In Man’s Bones 05/05/2024 | Zero wave radio

The entire program is in good hands, with Carles Aguilar. In recent centuries, social, technological and health improvements have increased the life expectancy of the population. Now, however, the coordinator of the physical exercise group of the Catalan Association of Family and Community Medicine (CAMFiC), Dr. “Although people can live longer, they do so with weaker physical functions and a lower quality of life, because we are more sedentary than we were years ago,” warns Montserrat Romaguera. Human development itself, especially new mobile technologies, encourages stability. And they do so with alarming data. In fact, we know that the European population engages in little physical activity and sport. According to the Eurobarometer, 45% of adult citizens in the 27 EU countries have never exercised or played sports, and a third of them do not do it enough. This sedentary lifestyle causes 10,000 premature deaths annually in Europe and about 1,070 in Spain.

“Pharmacogenetics”, an integral part of precision personalized medicine, studies how a person’s genetic variants affect the way they respond to drugs, both in terms of effectiveness and toxicity, and its main goal is to create individualized drug treatments, based on the genetic profile of each patient, with the aim of increasing The effectiveness of the treatments provided and reducing the side effects caused by the medications. Pharmacogenetics allows specialists to use each individual’s genetic profile to choose the most effective and safe drug for each patient and determine the most appropriate dose, leading to a reduction of up to 28% in adverse reactions, as recently published in The Lancet. Currently, in Spain, about 53% of approved medicines have some genetic biomarker associated with their technical data sheet, especially in oncology, and it is expected that in the future the choice of drug, dose and safety plan will be conditional on the inclusion of pharmacological biomarkers. Carles Aguilar interviewed Cristina Rodriguez, President of the Spanish Society of Pharmacogenetics and Pharmacogenomics.

Osteoarthritis, depending on the affected area, in more advanced degrees, becomes a disabling disease, preventing the patient from carrying out normal daily activity. The simple act of getting up from a chair and starting to walk can become very painful. Going down the stairs increases in intensity and pain after exercising. Moderate exercise or light walking leads to inflammation in osteoarthritis joints. One of the latest developments in the treatment of joint pain is regenerative medicine. The doctor explains it to us. Humberto Lucertales, Director of Medicentre.

High blood pressure, or high blood pressure, is called the “silent killer.” The comparison is justified, because at the beginning of the disease a person may not feel any symptoms for a long time. Nearly 46% of adults with high blood pressure don’t know they have it. Blood pressure rises slowly over time, and it’s not always clear what causes this condition, but it is known that the risk of high blood pressure increases. The damage caused by high blood pressure to the circulatory system is significant. Untreated high blood pressure can lead to very serious consequences: myocardial infarction, stroke, cardiac arrest, kidney failure, vision loss, or impotence. The doctor explains it to us. José Abellán, Director of the Chair of Cardiovascular Risk at the Catholic University of Murcia and President of the Murcia Society of Arterial Hypertension and Cardiovascular Risk.

The promising results obtained in the clinical trial of a leading advanced therapy drug called PeriCord, which seeks to repair the heart in patients who have suffered a heart attack, confirm the feasibility of new treatments based on the application of stem cells and “tissues”. Engineering to promote regeneration of damaged tissue. This new drug, which comes from umbilical cord and pericardial stem cells from tissue donors, is the product of tissue engineering (a type of advanced treatment that combines cells and tissues optimized in the laboratory), is world-leading and applies to patients who are candidates for coronary artery bypass surgery. , with the benefit of intervention. Its job is to repair the scar left in the area of ​​the heart damaged by the heart attack, which lost the ability to beat when blood stopped circulating there. The first intervention of this new treatment in almost 4 years was the result of a collaboration between the ICREC (Heart Failure and Cardiac Regeneration) group of the German Research Institute Trias i Pujol (IGTP) and the Blood and Tissue Bank (BST). Due to the success, a study was initiated to prove its clinical safety. The study included 12 patients who were candidates for coronary artery bypass surgery, 7 of whom were treated with biotransplantation and 5 without it, to compare results. Carles Aguilar talks to Christina Pratt, D.D. in Biology and Head of Production of Advanced Therapies for Blood and Tissue Banks.